Good morning. Welcome to the Jefferies London Healthcare Conference. My name is Dennis Ding, biotech analyst here at Jefferies. I have the wonderful pleasure of having Recursion Pharmaceuticals up ...

At the core of every AI coding agent is a technology called a large language model (LLM), which is a type of neural network ...

Patronus AI unveiled “Generative Simulators,” adaptive “practice worlds” that replace static benchmarks with dynamic reinforcement-learning environments to train more reliable AI agents for complex, ...

Summary In this episode of The Defenders Log, Paul Mockapetris, the architect of DNS, discusses the evolving role of the Domain Name System from a simple directory to a sophisticated security tool. He ...

A new research paper reframes the simulation hypothesis, asking whether reality could be simulated and what science can test.

In 2025, Anthropic will grow from $1 billion to $9 billion in ARR (annual recurring revenue). OpenAI, meanwhile, will go from ...

Biopharma may see a happier year ahead in 2026 than in recent years, according to analysts at William Blair. For one thing, the industry’s top stocks have recovered from lows that stretched into last ...

This article, presented in the backdrop of the debates on the state of political theory in India, argues that the terms of debate need to shift to include the question of method of doing political ...

Adderall, Ritalin and other stimulants prescribed for attention-deficit/hyperactivity disorder seem to work on brain areas ...

Recursion Pharmaceuticals (RXRX) is drawing renewed attention after the appointment of Najat Khan as CEO and news of a narrowing net loss, both viewed as signals of improving execution. Investors also ...